Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis

Nature Medicine

Volumn 20, Issue 4, 2014, Pages 408-414

  Suragani, Rajasekhar N V S ^a   Cadena, Samuel M ^a   Cawley, Sharon M ^a   Sako, Dianne ^a   Mitchell, Dianne ^a   Li, Robert ^a   Davies, Monique V ^a   Alexander, Mark J ^a   Devine, Matthew ^a   Loveday, Kenneth S ^a   Underwood, Kathryn W ^a   Grinberg, Asya V ^a   Quisel, John D ^a   Chopra, Rajesh ^b   Pearsall, R Scott ^a   Seehra, Jasbir ^a   Kumar, Ravindra ^a  

^a Acceleron Pharma   (United States)

^b Translational Development Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR 2B; GROWTH DIFFERENTIATION FACTOR; GROWTH DIFFERENTIATION FACTOR 11; LUSPATERCEPT; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; BONE MARROW; CELL POPULATION; CELL PROLIFERATION; COLONY FORMING UNIT; ERYTHROBLAST; ERYTHROCYTE COUNT; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; EX VIVO STUDY; EXTRAMEDULLARY HEMATOPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; IRON BINDING CAPACITY; LOSS OF FUNCTION MUTATION; MATURATION; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RETICULOCYTE; SPLEEN; SURFACE PLASMON RESONANCE; THERAPY EFFECT;

MURINAE; MUS;

ACTIVIN RECEPTORS, TYPE II; ANEMIA; ANIMALS; BONE MORPHOGENETIC PROTEINS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ERYTHROCYTE COUNT; ERYTHROID PRECURSOR CELLS; ERYTHROPOIESIS; ERYTHROPOIETIN; GROWTH DIFFERENTIATION FACTORS; HAPLORHINI; HEMATINICS; HUMANS; LIGANDS; MICE; MYELODYSPLASTIC SYNDROMES; RATS; RECOMBINANT FUSION PROTEINS; RETICULOCYTE COUNT; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN;

EID: 84898042418     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3512     Document Type: Article

References (43)

1. Bowen, D. What is ineffective erythropoiesis in myelodysplastic syndromes? Leuk. Lymphoma 18, 243-247 (1995).
2. Libani, I.V. et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in β-thalassemia. Blood 112, 875-885 (2008).
3. Eshghi, S., Vogelezang, M.G., Hynes, R.O., Griffith, L.G. & Lodish, H.F. α4β1 integrin and erythropoietin mediate temporally distinct steps in erythropoiesis: integrins in red cell development. J. Cell Biol. 177, 871-880 (2007).
4. Smith, R.E. Jr. The clinical and economic burden of anemia. Am. J. Manag. Care 16 (suppl.), S59-S66 (2010).
5. Hattangadi, S.M., Wong, P., Zhang, L., Flygare, J. & Lodish, H.F. From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. Blood 118, 6258-6268 (2011).
6. Tanno, T. & Miller, J.L. Iron loading and overloading due to ineffective erythropoiesis. Adv. Hematol. 2010, 358283 (2010).
7. Ginzburg, Y. & Rivella, S. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood 118, 4321-4330 (2011).
8. Cao, A., Moi, P. & Galanello, R. Recent advances in β-thalassemias. Pediatr. Rep. 3, e17 (2011).
9. Jabbour, E., Kantarjian, H.M., Koller, C. & Taher, A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 112, 1089-1095 (2008).
10. Rider, C.C. & Mulloy, B. Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. Biochem. J. 429, 1-12 (2010).
11. Yu, J. et al. Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature 330, 765-767 (1987).
12. Broxmeyer, H.E. et al. Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin. Proc. Natl. Acad. Sci. USA 85, 9052-9056 (1988).
13. Shiozaki, M., Kosaka, M. & Eto, Y. Activin A: a commitment factor in erythroid differentiation. Biochem. Biophys. Res. Commun. 242, 631-635 (1998).
14. Maguer-Satta, V. et al. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFβ family. Exp. Cell Res. 282, 110-120 (2003).
15. Akel, S., Petrow-Sadowski, C., Laughlin, M.J. & Ruscetti, F.W. Neutralization of autocrine transforming growth factor-β in human cord blood CD34+CD38?Lin? cells promotes stem-cell-factor-mediated erythropoietin-independent early erythroid progenitor development and reduces terminal differentiation. Stem Cells 21, 557-567 (2003).
16. Söderberg, S.S., Karlsson, G. & Karlsson, S. Complex and context dependent regulation of hematopoiesis by TGF-β superfamily signaling. Ann. NY Acad. Sci. 1176, 55-69 (2009).
17. Shav-Tal, Y. & Zipori, D. The role of activin A in regulation of hemopoiesis. Stem Cells 20, 493-500 (2002).
18. Blank, U. & Karlsson, S. The role of Smad signaling in hematopoiesis and translational hematology. Leukemia 25, 1379-1388 (2011).
19. Shiozaki, M. et al. Evidence for the participation of endogenous activin A/erythroid differentiation factor in the regulation of erythropoiesis. Proc. Natl. Acad. Sci. USA 89, 1553-1556 (1992).
20. Zhou, L. et al. Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS. Blood 112, 3434-3443 (2008).
21. Cadena, S.M. et al. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J. Appl. Physiol. 109, 635-642 (2010).
22. Suragani, R.N. et al. Heme-regulated eIF2α kinase activated Atf4 signaling pathway in oxidative stress and erythropoiesis. Blood 119, 5276-5284 (2012).
23. Socolovsky, M. et al. Ineffective erythropoiesis in Stat5a?/?5b?/? mice due to decreased survival of early erythroblasts. Blood 98, 3261-3273 (2001).
24. Liu, Y. et al. Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood 108, 123-133 (2006).
25. Chen, K. et al. Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis. Proc. Natl. Acad. Sci. USA 106, 17413-17418 (2009).
26. Camaschella, C. BMP6 orchestrates iron metabolism. Nat. Genet. 41, 386-388 (2009).
27. McPherron, A.C., Lawler, A.M. & Lee, S.J. Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11. Nat. Genet. 22, 260-264 (1999).
28. Wu, H.H. et al. Autoregulation of neurogenesis by GDF11. Neuron 37, 197-207 (2003).
29. Kim, J. et al. GDF11 controls the timing of progenitor cell competence in developing retina. Science 308, 1927-1930 (2005).
30. Loffredo, F.S. et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 153, 828-839 (2013).
31. Lin, Y.W., Slape, C., Zhang, Z. & Aplan, P.D. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood 106, 287-295 (2005).
32. Paulson, R.F., Shi, L. & Wu, D.C. Stress erythropoiesis: new signals and new stress progenitor cells. Curr. Opin. Hematol. 18, 139-145 (2011).
33. Iancu-Rubin, C. et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp. Hematol. 41, 155-166.e17 (2013).
34. Sherman, M.L. et al. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. J. Clin. Pharmacol. 53, 1121-1130 (2013).
35. Sako, D. et al. Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J. Biol. Chem. 285, 21037-21048 (2010).
36. Lee, H.B. & Blaufox, M.D. Blood volume in the rat. J. Nucl. Med. 26, 72-76 (1985).
37. Lau, A.L., Kumar, T.R., Nishimori, K., Bonadio, J. & Matzuk, M.M. Activin βC and βE genes are not essential for mouse liver growth, differentiation, and regeneration. Mol. Cell. Biol. 20, 6127-6137 (2000).
38. Menon, M.P. et al. Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. J. Clin. Invest. 116, 683-694 (2006).
39. Ignotz, R.A. & Honeyman, T. TGF-β signaling in A549 lung carcinoma cells: lipid second messengers. J. Cell. Biochem. 78, 588-594 (2000).
40. Scharpfenecker, M. et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci. 120, 964-972 (2007).
41. Townson, S.A. et al. Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex. J. Biol. Chem. 287, 27313-27325 (2012).
42. Roy, C.N. et al. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 109, 4038-4044 (2007).
43. Koulnis, M. et al. Identification and analysis of mouse erythroid progenitors using the CD71/TER119 flow-cytometric assay. J. Vis. Exp. 54, e2809 (2011).